Clinical Trial

Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-center, open-label, phase 1 dose escalation and dose expansion (safety confirmation) trial to evaluate the safety and tolerability of balixafortide and cosibelimab in patients with metastatic PDAC who progressed after SOC chemotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-13; most recent amendment 2025-11-17.
Trial Details
NCT Number NCT06981806
Lead Sponsor Arsen Osipov
Conditions Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment 24 participants
Start Date 2026-01
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2025-11-19